Author

N. E. Stone

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Organism:human· 1

Frequent Co-Authors

S. A. Jaramillo· 3 shared A. N. Jones· 2 shared B. M. Barker· 2 shared C. T. French· 2 shared D. R. Kollath· 2 shared E. W. Settles· 2 shared H. E. Nunnally· 2 shared H. L. Mead· 2 shared

Activity by Year

2020-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

S. A. Jaramillo

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants

K. E. Zarn, S. A. Jaramillo, A. R. Zapata, N. E. Stone, A. N. Jones, H. E. Nunnally, E. W. Settles, K. Ng, P. S. Keim, S. Knudsen, P. M. Nuijten, A. S. Tijsma, C. T. French

This study shows that stenoparib inhibits SARS-CoV-2 variants in vitro, with EC50 values ranging from 4.1 to 24.1 M, and combination with remdesivir enhances antiviral effects.

bioRxiv · Nov 3, 2021Microbiology

The K18-hACE2 Transgenic Mouse Model Recapitulates Non-Severe and Severe COVID-19 in Response to Infectious Dose of SARS-CoV-2 Virus

J. Yu, W. Dong, A. Li, J. Zhang, M. Caligiuri, S. Jaramillo, H. L. Mead, N. E. Stone, A. Jones, D. R. Kollath, V. K. Coyne, M. Yearsley, L.-S. Wang, B. M. Barker, P. Keim, T. Barr

The paper characterizes the K18-hACE2 mouse model's response to different SARS-CoV-2 doses, showing dose-dependent disease severity and recovery, and compares it to human COVID-19 pathology.

bioRxiv · May 8, 2021Microbiology

The Effect of Minnelide against SARS-CoV-2 in a Murine Model

M. C. Caballero Van Dyke, H. L. Mead, M. Bryant, K. L. Laux, D. R. Kollath, V. K. Coyne, K. J. Miller, N. E. Stone, S. A. Jaramillo, P. Keim, C. Milikowski, V. K. Gupta, S. M. Vickers, A. Saluja, M. R. Velagapudi, B. M. Barker

This study evaluates Minnelide's efficacy in treating SARS-CoV-2 infection in mice, showing reduced viral load, improved survival, and decreased inflammation.

bioRxiv · May 5, 2021 · PreprintMicrobiology

Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerase (PARP), blocks replication of the SARS-CoV-2 human coronavirus in vitro.

N. E. Stone, S. A. Jaramillo, A. N. Jones, A. J. Vazquez, M. Martz, L. M. Versluis, M. O. Raniere, H. E. Nunnally, K. E. Zarn, R. Nottingham, J. W. Sahl, D. M. Wagner, S. Knudsen, E. W. Settles, P. S. Keim, C. T. French

This paper evaluates stenoparib, a PARP inhibitor, for antiviral activity against SARS-CoV-2 and other coronaviruses in vitro, showing dose-dependent suppression and potential synergy with remdesivir.

bioRxiv · Nov 12, 2020 · PreprintMicrobiology